Powder: -20°C for 3 years | In solvent: -80°C for 1 year
LP-184 (Compound 6), referred to as an acylfulvene analog, demonstrates the ability to inhibit tumor growth with noteworthy anti-cancer efficacy observed across multiple cell lines, including ovarian, colon, prostate, and pancreatic.
产品描述 | LP-184 (Compound 6), referred to as an acylfulvene analog, demonstrates the ability to inhibit tumor growth with noteworthy anti-cancer efficacy observed across multiple cell lines, including ovarian, colon, prostate, and pancreatic. |
靶点活性 | HT29 cells:0.68 μM (IC50), AsPC-1 cells:16 μM (IC50), OVCAR-3 cells:0.6 μM (IC50), PC3:0.14 μM (IC50) |
体外活性 | LP-184 inhibits the growth of HT29, OVCAR-3, AsPC-1 and PC-3, with GI 50 s of 0.68, 0.6, 16 and 0.14 μM, respectively[1]. LP-184 displays IC 50 s of 800nM and 210 nM for anti-cancer activitie in the thymidine incorporation into cellular DNA (2 hour) and Trypan blue (48 hour) assay[1]. |
体内活性 | LP-184 (7.5 and 10 mg/kg; i.p.; 21 day) has potent 15 anti-tumor activity against MV522 tumors, producing 4/6 and 5/5 partial responses, respectively[1]. Animal Model: Mice (MV522 tumors)[1]Dosage: 7.5 and 10 mg/kg Administration: I.p; 21day Result: Effective agent for human anti-tumor therapy. |
分子量 | 304.346 |
分子式 | C16H20N2O4 |
CAS No. | 924835-67-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
LP-184 924835-67-6 LP 184 LP184 Inhibitor inhibitor inhibit